Remove Clinical Trials Remove Consumption Remove DEA Remove Medicine
article thumbnail

Understanding the Current Legal Status of Psychedelics in the United States

Cannabis Law Report

The first path, that of traditional medicine, currently offers patients limited options. The only psychedelic drug that is approved (outside of clinical trials) for psychiatric use—as opposed to anesthesia—through the traditional medical system is Ketamine. 2022 Active FDA Clinical Trials and State-Regulated Systems.

article thumbnail

Veriheal’s Innovation in Cannabis Scholarship 2020 Winners

Veriheal

These students showed knowledge and passion for the future of cannabis and posed revolutionary ideas rooted in their training across business, agriculture, biochemistry, public health, pharmacology, medicine, and liberal arts. . Essay: “Integrating Research and Medicine: Cannabis Related Treatment for Neurodegenerative Diseases”.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Cannabis Industry Leaders Speak With CLR on Current Delta 8 Issues In The Industry

Cannabis Law Report

Dr. Titus holds a Fellowship with the American Academy of Pain Management and clinical association with the American Association of Integrative Medicine. We used to have “medicinal alcohol” in our country, and this was only available via a doctor’s prescription during the Prohibition Era.

article thumbnail

Guest Post: Is CBD Legal? Federal & State Laws [2019]

Cannabis Law Report

However, CBD will provide many medicinal benefits including reducing inflammation, pain, anxiety, stress, migraines, seizures, depression, and the ability to obtain a much deeper sleep so you can wake up well rested and ready to tackle your daily tasks. CBD is completely non-psychoactive. You can find the list of medical conditions here.

article thumbnail

Report: “Key pharmacological differences between side effects of refined, pharmaceutical CBD formulations and whole plant extracts:”

Cannabis Law Report

Recent studies on the effectiveness of cannabidiol in the rare seizure disorders Dravet Syndrome and Lennox-Gastaut syndrome have prompted a biopharmaceutical company to perform clinical trials of its own to bring a cannabidiol based drug to the American market through the process of FDA approval. No hepatic side effects were noted.